Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients

Kevin C. Miller, Aref Al-Kali, Mithun V. Shah, William Hogan, Michelle A. Elliott, Kebede Begna, Naseema Gangat, Mrinal M Patnaik, David S. Viswanatha, Rong He, Patricia T Greipp, Lisa Sproat, James M Foran, Mark R Litzow, Hassan B. Alkhateeb

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Poor outcomes in elderly acute lymphoblastic leukemia (ALL) are well recognized, but the contributors are ill-defined. We characterized 124 patients ≥60 years old at our institution. The majority (n = 102, 82%) were treated with intensive chemotherapy. Of these, 8/102 (8%) died within the first 100 days; 92/102 (90%) achieved complete remission (CR/CRi). Only 31/124 (25%) patients underwent allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) for the entire cohort was 19.8 months. In a multivariate analysis, ECOG performance status ≥2, high white blood cell count, and high lactate dehydrogenase (at time of diagnosis) negatively influenced OS (p<.01). In a subgroup analysis of the intensive treatment group, BCR-ABL1+ patients had markedly better OS (hazard ratio 0.3, 95% CI 0.1–0.7; p<.01). In summary, despite few early deaths and a high CR/CRi rate, elderly ALL continues to have a poor prognosis, underscoring the need for more effective therapies.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Survival
Hematopoietic Stem Cell Transplantation
Leukocyte Count
L-Lactate Dehydrogenase
Multivariate Analysis
Drug Therapy
Therapeutics

Keywords

  • acute lymphoblastic leukemia (ALL)
  • BCR-ABL1; transplant
  • Elderly
  • survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Elderly acute lymphoblastic leukemia : a Mayo Clinic study of 124 patients. / Miller, Kevin C.; Al-Kali, Aref; Shah, Mithun V.; Hogan, William; Elliott, Michelle A.; Begna, Kebede; Gangat, Naseema; Patnaik, Mrinal M; Viswanatha, David S.; He, Rong; Greipp, Patricia T; Sproat, Lisa; Foran, James M; Litzow, Mark R; Alkhateeb, Hassan B.

In: Leukemia and Lymphoma, 01.01.2018.

Research output: Contribution to journalArticle

Miller, Kevin C. ; Al-Kali, Aref ; Shah, Mithun V. ; Hogan, William ; Elliott, Michelle A. ; Begna, Kebede ; Gangat, Naseema ; Patnaik, Mrinal M ; Viswanatha, David S. ; He, Rong ; Greipp, Patricia T ; Sproat, Lisa ; Foran, James M ; Litzow, Mark R ; Alkhateeb, Hassan B. / Elderly acute lymphoblastic leukemia : a Mayo Clinic study of 124 patients. In: Leukemia and Lymphoma. 2018.
@article{060b907a757844a28a1185bb08c06f3b,
title = "Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients",
abstract = "Poor outcomes in elderly acute lymphoblastic leukemia (ALL) are well recognized, but the contributors are ill-defined. We characterized 124 patients ≥60 years old at our institution. The majority (n = 102, 82{\%}) were treated with intensive chemotherapy. Of these, 8/102 (8{\%}) died within the first 100 days; 92/102 (90{\%}) achieved complete remission (CR/CRi). Only 31/124 (25{\%}) patients underwent allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) for the entire cohort was 19.8 months. In a multivariate analysis, ECOG performance status ≥2, high white blood cell count, and high lactate dehydrogenase (at time of diagnosis) negatively influenced OS (p<.01). In a subgroup analysis of the intensive treatment group, BCR-ABL1+ patients had markedly better OS (hazard ratio 0.3, 95{\%} CI 0.1–0.7; p<.01). In summary, despite few early deaths and a high CR/CRi rate, elderly ALL continues to have a poor prognosis, underscoring the need for more effective therapies.",
keywords = "acute lymphoblastic leukemia (ALL), BCR-ABL1; transplant, Elderly, survival",
author = "Miller, {Kevin C.} and Aref Al-Kali and Shah, {Mithun V.} and William Hogan and Elliott, {Michelle A.} and Kebede Begna and Naseema Gangat and Patnaik, {Mrinal M} and Viswanatha, {David S.} and Rong He and Greipp, {Patricia T} and Lisa Sproat and Foran, {James M} and Litzow, {Mark R} and Alkhateeb, {Hassan B.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1509318",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Elderly acute lymphoblastic leukemia

T2 - a Mayo Clinic study of 124 patients

AU - Miller, Kevin C.

AU - Al-Kali, Aref

AU - Shah, Mithun V.

AU - Hogan, William

AU - Elliott, Michelle A.

AU - Begna, Kebede

AU - Gangat, Naseema

AU - Patnaik, Mrinal M

AU - Viswanatha, David S.

AU - He, Rong

AU - Greipp, Patricia T

AU - Sproat, Lisa

AU - Foran, James M

AU - Litzow, Mark R

AU - Alkhateeb, Hassan B.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Poor outcomes in elderly acute lymphoblastic leukemia (ALL) are well recognized, but the contributors are ill-defined. We characterized 124 patients ≥60 years old at our institution. The majority (n = 102, 82%) were treated with intensive chemotherapy. Of these, 8/102 (8%) died within the first 100 days; 92/102 (90%) achieved complete remission (CR/CRi). Only 31/124 (25%) patients underwent allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) for the entire cohort was 19.8 months. In a multivariate analysis, ECOG performance status ≥2, high white blood cell count, and high lactate dehydrogenase (at time of diagnosis) negatively influenced OS (p<.01). In a subgroup analysis of the intensive treatment group, BCR-ABL1+ patients had markedly better OS (hazard ratio 0.3, 95% CI 0.1–0.7; p<.01). In summary, despite few early deaths and a high CR/CRi rate, elderly ALL continues to have a poor prognosis, underscoring the need for more effective therapies.

AB - Poor outcomes in elderly acute lymphoblastic leukemia (ALL) are well recognized, but the contributors are ill-defined. We characterized 124 patients ≥60 years old at our institution. The majority (n = 102, 82%) were treated with intensive chemotherapy. Of these, 8/102 (8%) died within the first 100 days; 92/102 (90%) achieved complete remission (CR/CRi). Only 31/124 (25%) patients underwent allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) for the entire cohort was 19.8 months. In a multivariate analysis, ECOG performance status ≥2, high white blood cell count, and high lactate dehydrogenase (at time of diagnosis) negatively influenced OS (p<.01). In a subgroup analysis of the intensive treatment group, BCR-ABL1+ patients had markedly better OS (hazard ratio 0.3, 95% CI 0.1–0.7; p<.01). In summary, despite few early deaths and a high CR/CRi rate, elderly ALL continues to have a poor prognosis, underscoring the need for more effective therapies.

KW - acute lymphoblastic leukemia (ALL)

KW - BCR-ABL1; transplant

KW - Elderly

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85054399164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054399164&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1509318

DO - 10.1080/10428194.2018.1509318

M3 - Article

C2 - 30277111

AN - SCOPUS:85054399164

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -